Literature DB >> 15096214

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells.

Satomi Onoue1, Yuki Ohmori, Kosuke Endo, Shizuo Yamada, Ryohei Kimura, Takehiko Yajima.   

Abstract

Chronic obstructive pulmonary disease is a major clinical disorder usually associated with cigarette smoking. A central feature of chronic obstructive pulmonary disease is inflammation coexisting with an abnormal protease/antiprotease balance, leading to apoptosis and elastolysis. In an in vitro study of rat lung alveolar L2 cells, cigarette smoke extract (CSE) induced apoptotic cell death. Exposure of L2 cells to CSE at a concentration of 0.25% resulted in a 50% increase of caspase-3 and matrix metalloproteinase (MMP) activities. Specific inhibitors for caspases and MMPs attenuated the cytotoxicity of CSE. RT-PCR amplification identified VPAC2 receptors in L2 cells. A radioligand-binding assay with (125)I-labeled vasoactive intestinal peptide (VIP) found high affinity and saturable (125)I-labeled VIP-binding sites in L2 cells. VIP and pituitary adenylate cyclase-activating polypeptide (PACAP27) were approximately equipotent for both VIP receptor binding and stimulation of cAMP production in L2 cells. Both neuropeptides, at concentrations higher than 10(-13) m, produced a concentration-dependent inhibition of CSE-induced cell death in L2 cells. VIP, at 10(-7) m, reduced CSE-stimulated MMP activity and caspase-3 activation. The present study has shown that VIP and PACAP27 significantly attenuate the cytotoxicity of CSE through the activation of VPAC2 receptor, and the protective effect of VIP may partly be the result of a reduction in the CSE-induced stimulation of MMPs and caspases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15096214     DOI: 10.1111/j.1432-1033.2004.04086.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  11 in total

1.  Role of vasoactive intestinal peptide in hyperoxia-induced injury of primary type II alveolar epithelial cells.

Authors:  Xiaoxiao Ao; Fang Fang; Feng Xu
Journal:  Indian J Pediatr       Date:  2010-10-07       Impact factor: 1.967

Review 2.  Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.

Authors:  Satomi Onoue; Shingen Misaka; Shizuo Yamada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

Review 3.  PACAP deficiency as a model of aging.

Authors:  D Reglodi; T Atlasz; E Szabo; A Jungling; A Tamas; T Juhasz; B D Fulop; A Bardosi
Journal:  Geroscience       Date:  2018-10-22       Impact factor: 7.713

4.  Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics.

Authors:  Ag Mathioudakis; V Chatzimavridou-Grigoriadou; E Evangelopoulou; Ga Mathioudakis
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

5.  Therapeutic efficacy of stable analogues of vasoactive intestinal peptide against pathogens.

Authors:  Jenny Campos-Salinas; Antonio Cavazzuti; Francisco O'Valle; Irene Forte-Lago; Marta Caro; Stephen M Beverley; Mario Delgado; Elena Gonzalez-Rey
Journal:  J Biol Chem       Date:  2014-04-04       Impact factor: 5.157

6.  VIP down-regulates the inflammatory potential and promotes survival of dying (neural crest-derived) corneal endothelial cells ex vivo: necrosis to apoptosis switch and up-regulation of Bcl-2 and N-cadherin.

Authors:  Shay-Whey M Koh; Jason Cheng; Rebecca M Dodson; Chao-Yar T Ku; Cara J Abbondandolo
Journal:  J Neurochem       Date:  2009-02-24       Impact factor: 5.372

Review 7.  Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review.

Authors:  Dongmei Wu; Dongwon Lee; Yong Kiel Sung
Journal:  Respir Res       Date:  2011-04-11

8.  Azithromycin attenuates cigarette smoke extract-induced oxidative stress injury in human alveolar epithelial cells.

Authors:  Miaomiao Chen; Tuo Yang; Xiangiyu Meng; Tieying Sun
Journal:  Mol Med Rep       Date:  2015-01-20       Impact factor: 2.952

9.  Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal Peptide.

Authors:  Jihad Georges Youssef; Mohammad Z Bitar; Faisal Zahiruddin; Mukhtar Al-Saadi; Mahmoud Elshawwaf; Simon Yau; Ahmad Goodarzi; Jonathan C Javitt
Journal:  Crit Care Explor       Date:  2022-01-05

10.  VIP Stabilizes the Cytoskeleton of Schlemm's Canal Endothelia via Reducing Caspase-3 Mediated ZO-1 Endolysosomal Degradation.

Authors:  Xiaotong Lou; Qianxue Mou; Bowen Zhao; Jingqiu Huang; Ke Yao; Zhaoxia Luo; Meng Ye; Yuanyuan Hu; Qiming Duan; Xing Li; Zheng Wen; Zhiqi Chen; Hong Zhang; Yin Zhao
Journal:  Oxid Med Cell Longev       Date:  2021-09-13       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.